This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Academic Research Centers Join Forces To Improve Clinical Research

MADISON, Wis., March 7, 2013 /PRNewswire/ -- A collaborative group of academic research organizations is revolutionizing the way clinical research is conducted through their participation in the Research Resonance Network. The network's host, Forte Research Systems, Inc., has announced the availability of a new online home for the group along with a suite of tools for improving clinical research processes. Registration is now open to access the first resource to go live on the network, the Site Metrics Registry. This registry is the culmination of seven years of effort driven, in large part, by 20 leading academic medical centers including the Yale Center for Clinical Investigation and Indiana University Simon Cancer Center.


There is a growing interest in improving the processes around clinical study execution. Most stakeholders in the drug development industry agree that the current environment is not sustainable. Similarly, the National Cancer Institute and the National Center for Advancing Translational Sciences have undertaken major efforts for process improvement as they seek avenues for speeding up the development of new therapies.

"A cursory glance at the current drug development landscape reveals ever-increasing unhealthy trends. Protocols are getting more complicated, study startup is labor intensive and inefficient, and centers face challenges in everything from compliance to financial viability," said Srini Kalluri, Forte's founder, president, CEO and Chief Customer Officer. "By allowing centers to share, compare, and take action based on their data, the Research Resonance Network helps centers work together to find better solutions."

The desire for improvement is evident in such initiatives as TransCelerate BioPharma, Inc., the Clinical Trials Transformation Initiative (CTTI), and the Alliance for Clinical Research Excellence and Safety (ACRES), all of which strive to bring key stakeholders together to find ways to improve clinical research.

Under the leadership provided by the participating centers, the Research Resonance Network Site Metrics Registry, hosted at, is already delivering value with its library of standard data definitions for a large number of performance measurements, also referred to as "metrics." The registry contains metrics for: evaluating cycle times in such areas as IRB approval and contracting; measuring the size of clinical research operations in such areas as the number of open protocols and new subject accruals; and measuring effort in areas that include data management and budgeting.

"We've taken the initiative to work with Forte on this effort because we believe it's an invaluable tool for academic medical centers and Clinical and Translational Science Award (CTSA) sites. Knowing how our peer institutions are doing helps us to improve our own clinical research processes and timelines," said Robert Sherwin, MD, CNH, Long Professor of Medicine at the Yale School of Medicine and director of the Yale Center of Clinical Investigation. 

Using sophisticated security mechanisms, the registry allows centers to contribute their data and then compare their own performance to anonymous data aggregated from their peers. Forte acts as the trusted third party ensuring that the privacy of all participants is protected and nothing is ever shared with unauthorized individuals or in any way that allows the participating centers to be identified.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs